Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ antagonists & inhibitors
Disease Progression
Female
Follow-Up Studies
Humans
Liver Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Lymphatic Metastasis
Male
Middle Aged
Nivolumab
/ therapeutic use
Peritoneal Neoplasms
/ drug therapy
Prognosis
Retrospective Studies
Stomach Neoplasms
/ drug therapy
Survival Rate
Gastric cancer
Hyperprogressive disease
Nivolumab
PD-1 inhibitor
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
01
11
2018
accepted:
25
12
2018
pubmed:
11
1
2019
medline:
31
12
2019
entrez:
11
1
2019
Statut:
ppublish
Résumé
Hyperprogressive disease (HPD) during treatment with anti-programmed death-1/programmed death-ligand 1 monoclonal antibodies has anecdotally been reported in some types of cancers, but is not well-characterized in patients with advanced gastric cancer (AGC). Total 62 AGC patients treated with nivolumab in a single institution from September 2017 to April 2018 were enrolled in this study. Tumor responses were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1, and HPD was defined as ≥ two fold increase in tumor growth rate. Clinicopathological and molecular characteristics associated with HPD were also investigated. Thirteen of 62 patients (21%) developed HPD after nivolumab treatment. Overall survival (OS) and progression-free survival (PFS) were significantly shorter in patients with HPD than in patients without HPD (median OS: 2.3 months vs. not reached, P < 0.001; median PFS: 0.7 months vs. 2.4 months, P < 0.001). Liver metastases (77% vs. 41%), Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or 2 (77% vs. 29%), and a large sum of target lesion diameters at baseline (median 104.2 mm vs. 44.9 mm) were significantly associated with HPD. Absolute neutrophil count (ANC) and C-reactive protein (CRP) level significantly increased in the first 4 weeks in only patients with HPD. HPD was observed in AGC patients treated with nivolumab and correlated with some clinicopathological characteristics. Elevations in ANC and CRP levels upon treatment might indicate HPD.
Sections du résumé
BACKGROUND
Hyperprogressive disease (HPD) during treatment with anti-programmed death-1/programmed death-ligand 1 monoclonal antibodies has anecdotally been reported in some types of cancers, but is not well-characterized in patients with advanced gastric cancer (AGC).
METHODS
Total 62 AGC patients treated with nivolumab in a single institution from September 2017 to April 2018 were enrolled in this study. Tumor responses were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1, and HPD was defined as ≥ two fold increase in tumor growth rate. Clinicopathological and molecular characteristics associated with HPD were also investigated.
RESULTS
Thirteen of 62 patients (21%) developed HPD after nivolumab treatment. Overall survival (OS) and progression-free survival (PFS) were significantly shorter in patients with HPD than in patients without HPD (median OS: 2.3 months vs. not reached, P < 0.001; median PFS: 0.7 months vs. 2.4 months, P < 0.001). Liver metastases (77% vs. 41%), Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or 2 (77% vs. 29%), and a large sum of target lesion diameters at baseline (median 104.2 mm vs. 44.9 mm) were significantly associated with HPD. Absolute neutrophil count (ANC) and C-reactive protein (CRP) level significantly increased in the first 4 weeks in only patients with HPD.
CONCLUSIONS
HPD was observed in AGC patients treated with nivolumab and correlated with some clinicopathological characteristics. Elevations in ANC and CRP levels upon treatment might indicate HPD.
Identifiants
pubmed: 30627987
doi: 10.1007/s10120-018-00922-8
pii: 10.1007/s10120-018-00922-8
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
793-802Références
BMC Res Notes. 2016 Jul 18;9:349
pubmed: 27431235
Ann Oncol. 2016 Jul;27(7):1354-6
pubmed: 27037297
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
J Thorac Oncol. 2017 Sep;12(9):e140-e141
pubmed: 28838713
J Clin Oncol. 2014 Jan 20;32(3):260-3
pubmed: 24297942
Gastric Cancer. 2019 Jan;22(1):69-76
pubmed: 29859006
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Rev Cancer. 2016 Jul;16(7):447-62
pubmed: 27339708
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849
pubmed: 29891725
Br J Cancer. 2016 Feb 16;114(4):381-7
pubmed: 26882063
J Thorac Dis. 2018 Feb;10(2):1124-1128
pubmed: 29607190
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Cancer Discov. 2018 Jan;8(1):49-58
pubmed: 29122777
Oncoimmunology. 2018 Jan 29;7(4):e1408747
pubmed: 29632720
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Oncol Lett. 2017 Aug;14(2):1766-1774
pubmed: 28789407